First Tracks Biotherapeutics Stock Climbs Nearly 8% as Celiac Drug Hopes Push Shares Up 160% in a Year
Shares of First Tracks Biotherapeutics Inc. rose nearly 8% on Tuesday, extending a long rally fueled by early clinical data on its experimental celiac disease drug.
The stock gained $3.87 to $53.57 in morning trading on the Nasdaq, above its previous high of just over $50. The company is valued at about $2.2 billion, and the shares are up about 160% over the past 52 weeks. Volume was about 269,000 shares by midmorning, compared with a three-month daily average of about 828,000.
The company did not announce any new information alongside Tuesday's gain, and it was not immediately clear what drove the move. The stock has climbed steadily since the company reported positive results last month from a key early-stage trial of its lead drug, ANB033.
First Tracks, based in San Diego, is a clinical-stage biotechnology company that develops antibody therapies for autoimmune and inflammatory diseases. It was spun off from AnaptysBio and began trading on April 20 under the ticker "TRAX," with about $180 million in cash. The stock opened its public life at about $17 and fell to a low of........
